| EPB164 | Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care | E-poster | Regimen simplification and switch studies |
| EPB168 | Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study | E-poster | Regimen simplification and switch studies |
| EPB161 | Switching EFV/FTC/TDF to B/F/TAF or generic EFV/FTC/TDS in virologically suppressed adults with human immunodeficiency virus: a 96-week retrospective cohort | E-poster | Regimen simplification and switch studies |
| EPB112 | Switching ART Regimens is associated with greater weight gain in people living with HIV | E-poster | Weight gain |
| EPE220 | Sustaining the operations of Nigeria's treatment programme through the development of an ART management model | E-poster | Approaches to achieving sustainability, including sustainable financing for civil society |
| EPE410 | Sustaining clinic engagement and viral suppression through modifications to HIV care models during the COVID-19 pandemic: experiences in Uganda military health facilities | E-poster | Impact of COVID-19 on HIV treatment services |
| EPE336 | Sustained viral suppression among HIV positive women through a robust peer approach in m2m countries during COVID-19 Pandemic | E-poster | Innovative uses of data to strengthen systems and programmes |
| EPC057 | Sustained HIV viral suppression among people living with HIV in Trinidad and Tobago | E-poster | Risk factors for acquisition, infectivity and transmission of HIV |
| EPE219 | Sustainability of opioid agonist therapy (OAT) programsin 4 Eastern European and Central Asian countries in the context of transition from Global Fund support | E-poster | Approaches to achieving sustainability, including sustainable financing for civil society |
| EPE206 | Sustainability of community-based social services for key populations in Russia: problems and prospects of national investment programs | E-poster | National financing analyses and financing mechanisms for HIV, hepatitis and STI programmes and services |